Literature DB >> 31575798

Electro Cell Fusion for Hybridoma Production.

Edward A Greenfield.   

Abstract

Once a good immune response has developed in an animal and an appropriate screening procedure has been developed, the construction of hybridomas is ready to begin. The electro cell fusion (electrofusion) method uses an electrical field in the form of short, intense pulses to increase the permeability of the membrane. The resulting local perforation of the cell membrane induces the cells to fuse, forming hybridomas. Electrofusion is accomplished in three steps: Prealignment of the cells (convergence and cell contact), membrane fusion, and postalignment (rounding off the fused cells). This method has been applied successfully to hybridoma production with higher efficiency than routine polyethylene glycol fusion, allowing production of more hybrid cells.
© 2019 Cold Spring Harbor Laboratory Press.

Entities:  

Year:  2019        PMID: 31575798     DOI: 10.1101/pdb.prot103184

Source DB:  PubMed          Journal:  Cold Spring Harb Protoc        ISSN: 1559-6095


  3 in total

1.  Establishment of a Monoclonal Antibody against Human NTCP That Blocks Hepatitis B Virus Infection.

Authors:  Toshitada Takemori; Akiko Sugimoto-Ishige; Hironori Nishitsuji; Yushi Futamura; Michishige Harada; Tomomi Kimura-Someya; Takehisa Matsumoto; Teruki Honma; Miho Tanaka; Masami Yaguchi; Kyoichi Isono; Haruhiko Koseki; Hiroyuki Osada; Daiki Miki; Takashi Saito; Takashi Tanaka; Takehiro Fukami; Toshio Goto; Mikako Shirouzu; Kunitada Shimotohno; Kazuaki Chayama
Journal:  J Virol       Date:  2022-01-05       Impact factor: 5.103

Review 2.  Hybridoma technology: is it still useful?

Authors:  Jane Zveiter Moraes; Bárbara Hamaguchi; Camila Braggion; Enzo Reina Speciale; Fernanda Beatriz Viana Cesar; Gabriela de Fátima da Silva Soares; Juliana Harumi Osaki; Tauane Mathias Pereira; Rodrigo Barbosa Aguiar
Journal:  Curr Res Immunol       Date:  2021-03-22

3.  Potent Neutralizing Humanized Antibody With Topical Therapeutic Potential Against HPV18-Related Cervical Cancer.

Authors:  Bilian Huang; Linjing Zhu; Hongxia Wei; Haixia Shi; Doudou Zhang; Huanyun Yuan; Linlin Luan; Nan Zheng; Shijie Xu; Waqas Nawaz; Ying Hong; Xilin Wu; Zhiwei Wu
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.